Welcome to the international HTA database

Showing [23365 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2023	National Institute for Health and Care Excellence (NICE)	Semaglutide for managing overweight and obesity. NICE technology appraisal guidance 875
2023	National Institute for Health and Care Excellence (NICE)	Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma. NICE technology appraisal guidance 874
2023	National Institute for Health and Care Excellence (NICE)	Cannabidiol for treating seizures caused by tuberous sclerosis complex. NICE technology appraisal guidance 873
2023	National Institute for Health and Care Excellence (NICE)	Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies. NICE technology appraisal guidance 872
2023	National Institute for Health and Care Excellence (NICE)	Eptinezumab for preventing migraine. NICE technology appraisal guidance 871
2023	National Institute for Health and Care Excellence (NICE)	Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma. NICE technology appraisal guidance 870
2023	National Institute for Health and Care Excellence (NICE)	Teclistamab for treating relapsed or refractory multiple myeloma after 3 or more therapies (terminated appraisal). NICE technology appraisal guidance 869
2023	National Institute for Health and Care Excellence (NICE)	Vutrisiran for treating hereditary transthyretin-related amyloidosis. NICE technology appraisal guidance 868
2023	National Institute for Health and Care Excellence (NICE)	Mitapivat for treating pyruvate kinase deficiency (terminated appraisal). NICE technology appraisal guidance 867
2023	National Institute for Health and Care Excellence (NICE)	Regorafenib for previously treated metastatic colorectal cancer. NICE technology appraisal guidance 866
2023	National Institute for Health and Care Excellence (NICE)	Nivolumab with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma. NICE technology appraisal guidance 865
2023	National Institute for Health and Care Excellence (NICE)	Nintedanib for treating idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted. NICE technology appraisal guidance 864
2023	National Institute for Health and Care Excellence (NICE)	Somatrogon for treating growth disturbance in children and young people aged 3 years and over. NICE technology appraisal guidance 863
2023	National Institute for Health and Care Excellence (NICE)	Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments. NICE technology appraisal guidance 862
2023	National Institute for Health and Care Excellence (NICE)	Upadacitinib for treating active non-radiographic axial spondyloarthritis. NICE technology appraisal guidance 861
2023	National Institute for Health and Care Excellence (NICE)	Maribavir for treating refractory cytomegalovirus infection after transplant. NICE technology appraisal guidance 860
2023	National Institute for Health and Care Excellence (NICE)	Angiotensin II for treating vasosuppressor-resistant hypotension caused by septic or distributive shock (terminated appraisal). NICE technology appraisal guidance 859
2023	National Institute for Health and Care Excellence (NICE)	Lenvatinib with pembrolizumab for untreated advanced renal cell carcinoma. NICE technology appraisal guidance 858
2023	National Institute for Health and Care Excellence (NICE)	Nivolumab with platinum- and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma. NICE technology appraisal guidance 857
2023	National Institute for Health and Care Excellence (NICE)	Upadacitinib for treating moderately to severely active ulcerative colitis. NICE technology appraisal guidance 856
2023	National Institute for Health and Care Excellence (NICE)	Mobocertinib for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy. NICE technology appraisal guidance 855
2023	The Danish Health Technology Council (DHTC)	[High-tech hospital beds for use in intensive and neurological wards]
2023	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Tisagenlecleucel (reassessment after the deadline (diffuse large B-cell lymphoma, (DLBCL))]
2023	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Tisagenlecleucel (reassessment after the deadline: B-cell acute lymphoblastic leukaemia (ALL), relapsed/ refractory, 0 ≤ 25 years)]
2023	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Talquetamab (multiple myeloma, at least 3 prior therapies)]
2023	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Setmelanotide (new therapeutic indication: obesity and control of hunger, Bardet-Biedl syndrome, ≥ 6 years)]
2023	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Ivosidenib (cholangiocarcinoma with IDH1 R132 mutation, after at least 1 prior therapy)]
2023	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Lonapegsomatropin (growth failure due to growth hormone deficiency, ≥ 3 to < 18 years)]
2023	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Fenfluramine (new therapeutic indication: Lennox-Gastaut syndrome, add-on therapy, ≥ 2 years)]
2023	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Etranacogene dezaparvovec (haemophilia B)]
2023	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Belantamab mafodotin (reassessment after the deadline: multiple myeloma, at least 4 prior therapies, monotherapy)]
2023	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Ciltacabtagene autoleucel (relapsing/ refractory multiple myeloma, after at least 3 prior therapies)]
2023	Center for Drug Evaluation (CDE)	[Latest trend in consumption and utilization of schedule I and II controlled drugs - a nationwide population-based data in Taiwan
2023	Ontario Health	Carrier screening programs for cystic fibrosis, fragile X syndrome, hemoglobinopathies and thalassemia, and spinal muscular atrophy
2023	Ontario Health	Robotic-assisted hysterectomy for endometrial cancer in people with obesity
2023	Ontario Health	Robotic-assisted partial nephrectomy for kidney cancer
2023	National Authority for Assessment and Accreditation in Healthcare (INEAS)	[Autologous adipose-derived stem cells for chronic wounds treatment : Full HTA report]
2023	National Authority for Assessment and Accreditation in Healthcare (INEAS)	[Kadcyla® (trastuzumab emtansine) in the treatment of HER2-positive breast cancer : A rapid review]
2023	The Regional Health Technology Assessment Centre (HTA-centrum)	[Remote patient monitoring– an overview of systematic reviews for selected diagnosis groups]
2023	The Regional Health Technology Assessment Centre (HTA-centrum)	Efficacy and safety of advanced hybrid closed loop systems compared with multiple daily injections or open loop systems, in adults with type 1 diabetes
2023	The Regional Health Technology Assessment Centre (HTA-centrum)	General psychiatric management for patients with personality disorder and/or self-harm behaviour
2023	Center for Outcomes Research and Economic Evaluation for Health (C2H)	[Cost-effectiveness evaluation of andexanet alfa (Ondexxya)]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Odronextamab (diffuse large B-cell lymphoma in adults); assessment according to §35a Social Code Book V; search for disease registries]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Odronextamab (follicular lymphoma in adults); assessment according to §35a Social Code Book V; search for disease registries]
2023	Center for Drug Evaluation (CDE)	[Assessment of the optimal implementation strategy for pneumococcal vaccination policies in groups at high risk of invasive pneumococcal disease]
2023	Center for Drug Evaluation (CDE)	[Evaluation of the optimal fixed subsidies strategy for pneumococcal vaccination in the elderly]
2023	Center for Drug Evaluation (CDE)	[Review of domestic and international drug addiction replacement treatment policies and cost-effectiveness analysis of methadone treatment in Taiwan]
2023	Center for Drug Evaluation (CDE)	[Analysis of the effectiveness of various hemophilia treatments in Taiwan]
2023	Center for Drug Evaluation (CDE)	[Evaluation of the effectiveness of long-acting antipsychotic injections and future recommendations for mental health care in Taiwan's National Health Insurance System]
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[Newsletter: innovations in home support, at the crossroads of humanity and technology]
2023	Basque Office for Health Technology Assessment (OSTEBA)	[Massive parallel sequencing for the diagnosis of acute leukaemia]
2023	Health Sciences Institute in Aragon (IACS)	[Molecular study of common apoE gene polymorphisms associated with familial dysbetalipoproteinaemia and late-onset Alzheimer’s disease]
2023	Agency for Care Effectiveness (ACE)	KardiaMobile for the detection of atrial fibrillation
2023	Agency for Care Effectiveness (ACE)	AcQMap for patients with cardiac arrhythmia
2023	Agency for Care Effectiveness (ACE)	Rapid to aid the diagnosis of patients suspected of stroke
2023	Agency for Care Effectiveness (ACE)	HeartFlow FFRCT for the diagnosis of coronary artery disease
2023	Agency for Care Effectiveness (ACE)	Paige Prostate Detect to assist the diagnosis of prostate cancer
2023	Agency for Care Effectiveness (ACE)	The CADScor System as a rule-out test for symptomatic patients suspected to have coronary artery disease
2023	Agency for Care Effectiveness (ACE)	Optune for the treatment of newly diagnosed and recurrent glioblastoma
2023	Agency for Care Effectiveness (ACE)	MagTrace and SentiMag for locating sentinel lymph node in patients with breast cancer
2023	Agency for Care Effectiveness (ACE)	Zio XT for ambulatory ECG monitoring for patients suspected to have cardiac arrhythmia
2023	Agency for Care Effectiveness (ACE)	Cytosponge for the detection of patients with Barrett oesophagus
2023	Agency for Care Effectiveness (ACE)	Sirolimus-coated percutaneous transluminal coronary angioplasty balloon catheters (SCBs) for patients with coronary artery disease (CAD)
2023	Agency for Care Effectiveness (ACE)	Thoracic and abdominal endovascular repair (T/EVAR) for the structural support of aortic aneurysm
2023	Agency for Care Effectiveness (ACE)	Aortic hybrid stent graft for treating complex aortic disease
2023	Agency for Care Effectiveness (ACE)	SpaceOAR systems for rectum protection during prostate cancer treatment
2023	Agency for Care Effectiveness (ACE)	Minimally invasive glaucoma surgery (MIGS) implants for treating patients with mild to moderate primary open-angle glaucoma (POAG)
2023	Agency for Care Effectiveness (ACE)	Presbyopia-correcting intraocular lenses for treating patients with cataract
2023	Agency for Care Effectiveness (ACE)	Dexamethasone intravitreal implant for treating diabetic macular oedema, retinal vein occlusion and non-infectious uveitis
2023	Agency for Care Effectiveness (ACE)	Trastuzumab deruxtecan for previously treated HER2-positive metastatic breast cancer
2023	Agency for Care Effectiveness (ACE)	Trastuzumab deruxtecan for treating HER2-positive advanced gastric cancer after two or more therapies
2023	Agency for Care Effectiveness (ACE)	Botulinum toxin A for the management of focal spasticity of the lower limbs associated with stroke in adults
2023	Agency for Care Effectiveness (ACE)	Ixekizumab and secukinumab for treating active non-radiographic axial spondyloarthritis
2023	Agency for Care Effectiveness (ACE)	Romosozumab and teriparatide for treating osteoporosis
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Sirolimus (Facial angiofibroma in tuberous sclerosis) - Assessment according to §35a (1), Sentence 11, Social Code Book V]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Talquetamab (multiple myeloma) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Lonapegsomatropin (growth hormone deficiency) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Pitolisant (narcolepsy, with or without cataplexy, children and adolescents, 6-17 years) – Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Axicabtagene ciloleucel (DLBCL and HGBL, second line) – Addendum to Commission A23-66]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Bimekizumab (psoriatic arthritis) – Addendum to Commission A23-60]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Brolucizumab (neovascular age-related macular degeneration) – Benefit assessment according to §35a Social Code Book V (expiry of the decision)]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Routine practice data collection for etranacogene dezaparvovec (haemophilia B) acc. to the Law for More Safety in the Supply of Medicines (GSAV): Evaluation of the study protocol (Version 1.0) and the statistical analysis plan (Version 1.0) – Second addend]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Pegunigalsidase alfa (Fabry disease) – Benefit assessment according to §35a Social Code Book V]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Nivolumab (melanoma, adjuvant, stage IIB or IIC) – Benefit assessment according to §35a Social Code Book V]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Risdiplam (spinal muscular atrophy, < 2 months) – Benefit assessment according to §35a Social Code Book V]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Concept for routine practice data collection acc. to the Law for More Safety in the Supply of Medicines (GSAV) – exagamglogene autotemcel (beta-thalassaemia)]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Benefit assessment of bupropion, cytisine, nicotine and varenicline for tobacco cessation in severe tobacco dependence]
2023	Health Information and Quality Authority (HIQA)	18F-PSMA PET/CT in the staging of primary prostate cancer and the restaging of recurrent prostate cancer: evidence synthesis to support a generic justification decision
2023	Penn Medicine Center for Evidence-based Practice (CEP)	Antibiotic products for treatment of trauma-related osteomyelitis
2023	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Assessment of the volume-result relationship in specialized care of pediatric cancer]
2023	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Computerized clinical decision support systems for decision support in patients with breast, lung, colorectal or prostate cancer]
2023	Swiss Federal Office of Public Health (FOPH)	Calcitonin gene-related peptide antagonists for the prevention of migraine
2023	Swiss Federal Office of Public Health (FOPH)	Revascularisation versus optimal medical therapy (OMT) for the treatment of chronic coronary syndrome (CCS)
2023	Swiss Federal Office of Public Health (FOPH)	Folate tests for suspected folate deficiency
2023	Swiss Federal Office of Public Health (FOPH)	Oral anticoagulants for the prevention of stroke and systemic embolism in people with non-valvular atrial fibrillation
2023	NIHR Health Technology Assessment programme	A multifaceted intervention to reduce antibiotic prescribing among CHIldren with acute COugh and respiratory tract infection: the CHICO cluster RCT
2023	NIHR Health Technology Assessment programme	Tonsillectomy compared with conservative management in patients over 16 years with recurrent sore throat: the NATTINA RCT and economic evaluation
2023	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Health technology assessment framework: adaptation for digital health technology assessment]
2023	Health Technology Wales (HTW)	Solution-focused assessment tools for improving the treatment of people with psychosis and schizophrenia within secondary mental health services
2023	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Peripheral electrical nerve stimulation (PENS) therapy as treatment for refractory chronic neuropathic pain in adults: evaluation of safety, efficacy, clinical effectiveness, and cost-effectiveness]